Monday, June 17, 2013
The Supreme Court is expected to hand down decisions today on one or more critical cases. Noah Feldman, Harvard law professor, Bloomberg View columnist and author of Cool War: The Future of Global Competition comments on last week's gene patent opinion and offers analysis of today's rulings.
Thursday, June 13, 2013
By Blakeney Schick : Associate Producer, The Leonard Lopate Show
Earlier today, the Supreme Court ruled, in a unanimous decision, that human genes can not be patented. The decision will shaped medical research in the decades to come. To find out more about gene patenting, we've collected our interviews on how it works and why the US Patent Office had already offered tens of thousands patents on genes.
Friday, May 03, 2013
As the Supreme Court decides whether genes can be patented, one geneticist has taken matters into his own hands. Dr. Robert Nussbaum is less worried about the owning of genes and more concerned about the monopoly that private companies have over genetic intellectual property – specifically what the mutations in a gene might mean for his patient's health. He tells Brooke how he’s challenging the stranglehold on that information one patient at a time.
We contacted Myriad for comment and they responded:
“Nothing is more important to Myriad than helping to save and improve peoples’ lives and more than one million patients have benefitted from Myriad’s BRACAnalysis test for hereditary breast and ovarian cancer. As a result of Myriad’s $500 million investment in R&D, today more than 95 percent of patients in the U.S. have access to the BRACAnalysis test through private insurance or other coverage, and patients’ average out-of-pocket cost is only $100. Myriad also offers financial assistance programs or free testing for uninsured patients or those in need."
Modest Mouse - Here It Comes